Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

45.58 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Is Eli Lilly Starting an Nvidia-Style Run? ↗

Today 6:25 EDT

Lilly shares soared more than 18% in May.

Via The Motley Fool

Topics Artificial Intelligence

5 Best Growth Stocks for the Next 10 Years ↗

May 31, 2026

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Via MarketBeat

Topics Artificial Intelligence Economy

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗

May 30, 2026

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

Via The Motley Fool

The Smartest Growth Stocks to Buy With $2,000 Right Now ↗

May 30, 2026

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

Via The Motley Fool

Topics Artificial Intelligence

Stock Split Watch: Is Eli Lilly Next? ↗

May 30, 2026

Lilly has split its stock in the past.

Via The Motley Fool

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗

May 28, 2026

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Via The Motley Fool

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗

May 28, 2026

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Via MarketBeat

Topics Earnings

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗

May 27, 2026

There is no reason to panic just yet.

Via The Motley Fool

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗

May 27, 2026

Eli Lilly's fundamentals matter more than Trump's stock purchases.

Via The Motley Fool

Topics Government

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗

May 26, 2026

These players are seeing exciting results in clinical trials.

Via The Motley Fool

Don't Buy Viking Therapeutics Stock Until You Read This ↗

May 25, 2026

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Via The Motley Fool

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗

May 25, 2026

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

The Silver Lining of Last Week's Hims & Hers Earnings Miss ↗

May 21, 2026

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Via MarketBeat

Topics Earnings

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products

From MarketNewsUpdates.com

Via GlobeNewswire

Could Viking Therapeutics Be the Next Eli Lilly? ↗

May 21, 2026

Demand for weight loss drugs may fuel growth for more than one player.

Via The Motley Fool

Best Weight Loss Drug Stocks to Buy in 2026 ↗

May 20, 2026

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Via The Motley Fool

Topics Intellectual Property

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗

May 20, 2026

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Via MarketBeat

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗

May 18, 2026

This dark horse in the weight loss drug race is worth keeping on your watch list.

Via The Motley Fool

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗

May 18, 2026

These stocks could look like steals in a few years.

Via The Motley Fool

Topics Intellectual Property

Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? ↗

May 17, 2026

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Via The Motley Fool

Buy, Sell, or Hold Novo Nordisk at $46? ↗

May 15, 2026

Can Novo Nordisk thrive under intense competitive pressures?

Via The Motley Fool

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Via MarketBeat

Topics ETFs Intellectual Property

Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign? ↗

May 15, 2026

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

Via The Motley Fool

Topics Artificial Intelligence

Best Healthcare Stocks to Buy in 2026 ↗

May 14, 2026

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Via The Motley Fool

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗

May 14, 2026

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Via The Motley Fool

Is Novo Nordisk's Rebound for Real--or Just a Head Fake? ↗

May 13, 2026

The worst might be in the rearview mirror.

Via The Motley Fool

Novo Nordisk A/S Q1 Earnings Call Highlights ↗

May 13, 2026

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of...

Via MarketBeat

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.